Articles in this supplement focus on the global opioid crisis, including coverage of harm reduction approaches, health justice promotion, and lessons learned.
Resources and Tools
This publication describes the recent trends of drug overdose deaths in the United States (U.S.) and the benefits of adopting harm reduction approaches.
In Los Angeles, New York, Houston, Philadelphia, and Washington, D.C., a National Institutes of Health funded clinical trial, known as INTEGRA, is evaluating the efficacy of delivering integrated HIV and substance use disorder care via mobile clinics.
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
This document provides a quick overview of the federal discretionary funding programs that support essential aspects of the nation’s HIV response.
Achieving the goals of the Ending the HIV Epidemic (EHE) Initiative depends on doing more to strengthen communities, reduce the harm associated with drug use, and prevent disease transmission.
Because of naloxone’s ability to reverse opioid overdose and its ease of use, by July 15, 2017, all 50 states and the District of Columbia had passed legislation to improve naloxone access, as one strategy to reduce opioid overdose morbidity and mortality.